PARIS--(BUSINESS WIRE)--Cappella, Inc. (Cappella), a medical device company developing dynamic solutions for the treatment of coronary bifurcation disease, today revealed how its innovative Sideguard® coronary sidebranch technology will be featured in several scientific sessions at this week’s EuroPCR Congress in Paris, including a new European survey on the challenges in treating bifurcation disease. Developed to protect the ostium of the sidebranch, the Cappella Sideguard coronary sidebranch technology offers interventional cardiologists a dynamic, effective, and easy-to-use solution in the treatment of bifurcation disease. This next generation stent platform preserves the sidebranch of diseased coronary arteries by protecting the ostium and minimising plaque shift. Cappella is currently engaged in a large-scale registry of more than 250 patients in Europe which should further confirm the ease of use and the reduced TVF rate.
